<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406326</url>
  </required_header>
  <id_info>
    <org_study_id>BIO1TR/MLS/100209</org_study_id>
    <nct_id>NCT02406326</nct_id>
  </id_info>
  <brief_title>An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study.</brief_title>
  <acronym>meriT-2</acronym>
  <official_title>A Prospective Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meril Life Sciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meril Life Sciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi centre, prospective trial. 250 patients will be enrolled in the study.(10&#xD;
      patients per centre involving approximately 25 centres). Patients will be followed up&#xD;
      clinically for twelve months post-procedure at 1 month, 6 months &amp; 12 months. All patients&#xD;
      will have a repeat angiography at 8 months. Clinical follow-up will be maintained for years 3&#xD;
      &amp; 5 post-implant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi centre, prospective observational study. 250 patients will be enrolled in the&#xD;
      study. 10 patients per centre involving approximately 25 centres. All the patients will be&#xD;
      followed for twelve months post-procedure. All patients will have a repeat angiography&#xD;
      assessment at 8 months. An additional clinical follow-up will be maintained for years 3 &amp; 5&#xD;
      post-implant.&#xD;
&#xD;
      Approximately 250 patients with obstructive coronary artery disease with a vessel size&#xD;
      between ≥2.5 to ≤3.5 mm in diameter by visual estimate and who meet all eligibility criteria&#xD;
      will be treated with the Sirolimus Eluting Stent.&#xD;
&#xD;
      It is anticipated that the total length of the study will be 16 months: 4 months to complete&#xD;
      patient enrollment and 12 months for angiographic follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2009</start_date>
  <completion_date type="Actual">December 27, 2016</completion_date>
  <primary_completion_date type="Actual">December 27, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) days</measure>
    <time_frame>30 days</time_frame>
    <description>composite of Death, MI (both Q-wave and Non Q-wave MI), Emergent CABG, or Clinically driven TLR (repeat PCI or CABG) and measured percentage wise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Until 12 months</time_frame>
    <description>Major adverse cardiac events is defined as the aggregate of cardiac death, myocardial infarction (MI) attributed to target vessel, and any target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related SAEs</measure>
    <time_frame>Until 12 months</time_frame>
    <description>Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioghraphic stent thrombosis</measure>
    <time_frame>After 30 days until 12 months</time_frame>
    <description>Acute (In hospital), Subacute (post procedure until 30 days) and Late (after 30 days until 12 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic/Device success, Procedural Success, Clinically justified Target Lesion Revascularization</measure>
    <time_frame>At 12 months</time_frame>
    <description>Quantitative Coronary Angiography derived vessel parameters In stent and 5 mm proximal and 5 mm distal from the edge of the stent (In-segment), Acute Gain (mm), Mild (%), Late loss (mm) and Binary Restenosis (%) rate, In stent MLD pre, post and 8 months angiographic follow up.</description>
  </secondary_outcome>
  <enrollment type="Actual">250</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of 250 patients with an obstructive coronary artery&#xD;
        disease with few exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be ≥18 years of age;&#xD;
&#xD;
          2. Patient is an acceptable candidate for PTCA, Stenting, or Emergent CABG;&#xD;
&#xD;
          3. Symptomatic ischemic heart disease (CCS class 1-4 , Braunwald class IB, IC, IIB,&#xD;
             IIC,IIIB,IIIC) and/or objective evidence of myocardial ischemia;&#xD;
&#xD;
          4. TIMI (Thrombolysis In Myocardial Infarction) flow grade ≥ 2 ;&#xD;
&#xD;
          5. C.T.O's (Chronic Total Occlusions) and Bifurcation Lesions may also be attempted;&#xD;
&#xD;
          6. Target lesion stenosis is &gt;50% and &lt;100% ;&#xD;
&#xD;
          7. Target lesions are de novo;&#xD;
&#xD;
          8. Target lesions ≤ 35mm in length (by visual estimation) that can be treated (covered)&#xD;
             by one single study stent (13 to 40mm in length)&#xD;
&#xD;
          9. Target lesion located in a major epicardial coronary vessel with reference of ≥ 2.5 -&#xD;
             ≤ 3.5mm in diameter (by visual estimation)&#xD;
&#xD;
         10. Target lesions which can be covered by one stent, no overlapping allowed (lesion stent&#xD;
             ratio of at least 1.5)&#xD;
&#xD;
         11. The patient and/or his legal representative has been informed of the nature of the&#xD;
             study and agrees to its provisions and has provided a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General exclusion criteria:&#xD;
&#xD;
          1. Women of childbearing potential;&#xD;
&#xD;
          2. Impaired renal function (creatinine &gt; 2.0 mg/dl or 180 μmol/l);&#xD;
&#xD;
          3. Any patient who has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC&#xD;
             of &lt; 3,000 cells/mm3, or documented or suspected liver disease (including laboratory&#xD;
             evidence of Hepatitis;&#xD;
&#xD;
          4. Recipient of an organ (Heart, Kidney, Lung or Liver) transplant;&#xD;
&#xD;
          5. History of CVA or TIA within the last 3 months&#xD;
&#xD;
          6. Patient with a concomitant disease having a life expectancy of less than 12 months;&#xD;
&#xD;
          7. Known allergies or contraindication to mTOR inhibitor class of drugs (Sirolimus),&#xD;
             Aspirin, Clopidogrel Bisulphate (Plavix®), Heparin, Cobalt Chromium/Nickel, contrast&#xD;
             media;&#xD;
&#xD;
          8. Any significant medical condition which in the investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study such as an active infection or&#xD;
             peptic ulcer or upper GI bleeding;&#xD;
&#xD;
          9. Currently participating in an investigational drug or another device study, or subject&#xD;
             to inclusion in another investigational drug or another device study during follow-up.&#xD;
&#xD;
         10. Clinically relevant contraindication to aspirin, heparin, clopidogrel bisulphate,&#xD;
             including thrombocytopenia, neutropenia, or leukopenia&#xD;
&#xD;
         11. Patients with Cardiogenic Shock.&#xD;
&#xD;
        Angiographic Exclusion criteria:&#xD;
&#xD;
          1. Left main coronary artery disease with ≥ 50% stenosis,&#xD;
&#xD;
          2. Angiographic evidence of thrombus (thrombus larger than half the diameter of the&#xD;
             vessel and/or requiring other adjunctive interventions such as Angiojet, Exciser,&#xD;
             Thrombolysis, etc.),&#xD;
&#xD;
          3. Left Ventricular Ejection Fraction ≤30 %,&#xD;
&#xD;
          4. Saphenous Vein Graft Interventions, (S.V.G's)&#xD;
&#xD;
          5. Patients presenting with an ongoing Acute Myocardial Infarction (AMI),&#xD;
&#xD;
          6. Patients having undergone a PCI within 48 hours of an AMI episode.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Ashok Seth, FRCP, FACC,FMRCP, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Escorts Heart Institute &amp; Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Ajit Mullasari, DNB, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madras Medical Mission</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Rohit M Kumar, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advance Cardiac Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Samuel K Mathew, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Group of Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. G S Wander, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hero DMC Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. C. N. Manjunath, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sri Jayadeva Institute of Cardiovascular Sciences &amp; Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Thomas Alexander, FCSI, FICC, FACC, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kovai Medical Centre and Hospitals Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Suresh Vijan, MRCP, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis/Wockhardt Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Suhas Hardas, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poona Hopsital &amp; Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sunitha Abraham, DNB, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Narayana Hrudayalaya Institute of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Prabhakar Shetty, FACC, DM, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia Asia Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fortis Escorts Heart Institute &amp; Research Centre</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Asia Hospitals</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Jayadeva Institute of Cardiovascular Sciences &amp; Research</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560069</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Hrudayalaya Institute of Medical Sciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis/Wockhardt Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poona Hopsital &amp; Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharshtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Cardiac Centre</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hero DMC Heart Institute</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madras Medical Mission</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Group of Hospitals</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600081</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kovai Medical Centre and Hospitals Ltd</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.asiaintervention.org/asia-pacific-hotlines-at-tct-2015-bioresorbable-vascular-scaffolds-versus-metallic-stents-in-patients-with-coronary-artery-disease-absorb-china-trial/</url>
    <description>Study results at 12 month follow up</description>
  </link>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

